Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 17/20 | 0.67 |
| ▸ | NTSR1 | P30989 | 17/20 | 0.67 |
| ▸ | SORT1 | Q99523 | 15/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725007 | 0.96 | NTSR2 (0.71) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL31280899 | 0.89 | NTSR1 (0.74) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL30623611 | 0.87 | NTSR1 (0.65) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL30294171 | 0.86 | NTSR1 (0.64) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL29414469 | 0.85 | NTSR1 (0.62) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL31018333 | 0.85 | CALCR (0.55) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL29940473 | 0.85 | NTSR1 (0.64) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL29361023 | 0.84 | NTSR1 (0.74) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL30361896 | 0.84 | NTSR1 (0.61) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL31151633 | 0.84 | NTSR1 (0.61) | NTSR2NTSR1SORT1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4700117-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ISCHEMIA AND CARDIOMYOPATHY | Summa Health (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12365876-B2 | Genetically modified stem cells | SDF BioPharma (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250041325-A1 | LIPID-BASED COMPOSITIONS AND METHODS THEREOF | UNITED STATES GOVERNMENT | 2025-02-06 | — | — | US | disclosed |
| US-20240360418-A1 | METHODS FOR REDUCING ELEVATED GLUCOSE LEVELS | SDF BIOPHARMA INC. | 2024-10-31 | — | — | US | disclosed |
| US-12122844-B2 | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies | CORNELL UNIVERSITY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240228586-A1 | COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS | THE UNIVERSITY OF CHICAGO (US) | 2024-07-11 | — | — | US | disclosed |
| US-12024568-B2 | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies | CORNELL UNIVERSITY (US) | 2024-07-02 | — | — | US | disclosed |
| US-11981928-B2 | Methods for reducing elevated glucose levels | SDF BIOPHARMA INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240150722-A1 | GENETICALLY MODIFIED STEM CELLS | SDF BIOPHARMA INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240139376-A1 | RECONSTITUTION OF EXTRACELLULAR MATRIXES FOR MUSCULOSKELETAL JOINT TISSUE REPAIR USING BIOMIMETIC BIOLOGIC AND SYNTHETIC FACTORS | RHODE ISLAND HOSPITAL | 2024-05-02 | — | — | US | disclosed |
| US-11857631-B2 | Protection and delivery of multiple therapeutic proteins | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-01-02 | — | — | US | disclosed |
| US-11739298-B2 | Genetically modified stem cells | SDF BIOPHARMA INC. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023107574-A2 | LIPID-BASED COMPOSITIONS AND METHODS THEREOF | THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230149511-A1 | TREATING AUTOIMMUNE DISEASES WITH GENETICALLY MODIFIED CELLS | Wallkill BioPharma, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20220281936-A1 | COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS | THE UNIVERSITY OF CHICAGO (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022174071-A2 | RECONSTITUTION OF EXTRACELLULAR MATRIXES FOR MUSCULOSKELETAL JOINT TISSUE REPAIR USING BIOMIMETIC BIOLOGIC AND SYNTHETIC FACTORS | RHODE ISLAND HOSPITAL (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220249672-A1 | Protection and Delivery of Multiple Therapeutic Proteins | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-08-11 | — | — | US | disclosed |
| WO-2022140781-A1 | USE OF STROMAL CELL-DERIVED FACTOR 1 (SDF1) AS A BIOMARKER FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220145262-A1 | GENETICALLY MODIFIED STEM CELLS | SDF BIOPHARMA INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-11298423-B2 | Protection and delivery of multiple therapeutic proteins | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228586-A1 | COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS | ADAM8, COL14A1, COL2A1 | NTSR2 4026/4885NTSR1 3229/4885SORT1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.